Achieve announces two patents granted by uspto for novel cytisinicline dosing and administration regimen

Seattle, wa and vancouver, bc / accesswire / august 11, 2021 / achieve life sciences, inc. (nasdaq:achv), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the united states patent and trademark office (uspto) has issued u.s. patent no. 11,083,715 and u.s. patent no.
ACHV Ratings Summary
ACHV Quant Ranking